肿瘤细胞治疗研究
ALL SOURCES
Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
使用未经处理的 PBMC 对犬 NK 免疫治疗似乎是安全且可能有效的，其在 NK 扩增、活化和细胞毒性方面与 CD5 清除相当或更优。
Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.
我们成功制备了犬B7-H3-CAR.CIK，平均CAR表达率为39% ± 2，免疫表型与未转导（NTD）对照相比未发生改变（CD3 = 92% ± 3，CD8 = 87% ± 7；CD4 = 49% ± 5；CD5 = 77% ± 0.1；NKp46 = 83% ± 5）。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
